Evaluation of the genotoxicity of cis-bis(3-aminoflavone) dichloroplatinum(II) in comparison with cis-DDP

Mutation Research - Genetic Toxicology and Environmental Mutagenesis

Volumn 558, Issue 1-2, 2004, Pages 93-110

  Kosmider, Beata ^a   Wyszynska, Kalina ^b   Janik Spiechowicz, Ewa ^b   Osiecka, Regina ^a   Zyner, Elzbieta ^c   Ochocki, Justyn ^c   Ciesielska, Ewa ^c   Wasowicz, Wojciech ^b  

^a UNIVERSITY OF LODZ   (Poland)

^b NOFER INSTITUTE OF OCCUPATIONAL MEDICINE   (Poland)

^c MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Ames assay; Chromosomal aberration assay; cis Diamminedichloroplatinum(II); cis bis(3 Aminoflavone)dichloroplatinum(II); Micronucleus assay; Sister chromatid exchange assay

Indexed keywords

BIS(3 AMINOFLAVONE)DICHLOROPLATINUM; CISPLATIN; CLASTOGEN; PLATINUM DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; BACTERIAL STRAIN; CELL NUCLEUS; CELL PROLIFERATION; CHROMOSOME ABERRATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOSTASIS; CYTOTOXICITY; FEMALE; GENE MUTATION; GENOTOXICITY; GENOTYPE; HUMAN; HUMAN CELL; LYMPHOCYTE; METABOLIC ACTIVATION; MICRONUCLEUS TEST; MITOSIS INHIBITION; MITOSIS RATE; MUTAGENICITY; NONHUMAN; PRIORITY JOURNAL; SALMONELLA TYPHIMURIUM; SISTER CHROMATID EXCHANGE;

SALMONELLA TYPHIMURIUM; UNIDENTIFIED AGENTS;

EID: 1242317096     PISSN: 13835718     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mrgentox.2003.11.006     Document Type: Article

References (59)

1. Wong E., Giandomenico C.M. Current status of platinum-based antitumor drugs. Chem. Rev. 99:1999;2451-2466.
2. B.I. Sikic, Antineoplastic agents, in: C.R. Craig, R.E. Stitzel (Eds.), Modern Pharmacology, Little, Brown and Company, Boston, 1982, p. 787.
3. Ferguson L.R., Pearson A.E. The clinical use of mutagenic anticancer drugs. Mutat. Res. 355:1996;1-12.
4. Nijveldt R.J., Nood E., Hoorn D.E.C., Boelens P.G., Norren K., Leeuwen P.A.M. Flavonoids: a review of probable mechanisms of action and potential applications. Am. J. Clin. Nutr. 74:2001;418-425.
5. Zyner E., Graczyk J., Ochocki J. Pt(II) and Pd(II) complexes of 3-aminoflavone: in vitro and in vivo evaluation. Pharmazie. 54:1999;945-946.
6. Waters M.D., Stack H.F., Jackson M.A. Genetic toxicology data in the evaluation of potential human environmental carcinogens. Mutat. Res. 437:1999;21-49.
7. Müller R., Kikuchi Y., Probst G., Schechtman L., Shimada H., Sofuni T., Tweats D. ICH-harmonised guidanced on genotoxicity testing of pharmaceuticals: evolution. Mutat. Res. 436:1999;195-225.
8. Marzin D. The position of the in vitro micronucleus test within the battery of screening for genotoxic potential determination and the regulatory guidelines. Mutat. Res. 392:1997;175-181.
9. Miller B., Pötter-Locher F., Seelbach A., Stopper H., Utesch D., Madle S. Evaluation of the in vitro micronucleus test as an alternative to the in vitro chromosomal aberration assay: position of the GUM working group on the in vitro micronucleus test. Mutat. Res. 410:1998;81-116.
10. J. Ochocki, E. Zyner, Patent No. P.185585 (2003).
11. Lowry O.H., Rosenbrough N.J., Farr A.L., Randall R.J. Protein measurement with Folin phenol reagent. J. Biol. Chem. 193:1951;265-275.
12. Maron D.M., Ames B.N. Revised methods for the Salmonella mutagenicity test. Mutat. Res. 113:1983;173-215.
13. Mortelmans K., Zeiger E. The Ames Salmonella/microsome mutagenicity assay. Mutat. Res. 455:2000;29-60.
14. Kirkland D.J. Statistical evaluation of mutagenicity test data: recommendations of the UK environmental mutagen society. Environ. Health Perspect. Suppl. 102:1994;43-47.
15. Galloway S.M., Aardema M.J., Ishidate M.I. Jr., Ivett J.L., Kirkland D.J., Morita T., Mosesso P., Sofuni T. Report from working group on in vitro tests for chromosomal aberrations. Mutat. Res. 312:1994;241-261.
16. Kirkland D. Chromosome aberration testing in genetic toxicology - past, present and future. Mutat. Res. 404:1998;173-185.
17. Preston R.J., San Sebastian J.R., Mc Fee A.F. The in vitro human lymphocyte assay for assessing the clastogenicity of chemical agents. Mutat. Res. 189:1987;175-183.
18. OECD Guideline for the testing of chemicals, In vitro mammalian chromosome aberration test, 473 (1997) 1/10-9/10.
19. ISCN, An International System for human cytogenetics nomenclature, Report of the standing committee on human cytogenetic nomenclature, S. Karger (Ed.), Basel, Munchen, Paris, London, New York, New Delhi, Singapore, Tokyo, Sydney, 1985, pp. 66-69.
20. Bozsakyová E., Chalupa I., Šebová L., Slameòová D. Chromosomal aberrations, sister chromatid exchanges and micronuclei induced by pentoxifyline in in vitro cultivated Chinese hamster cells (V79) and human blood lymphocytes. Mutat. Res. 497:2001;63-70.
21. Rojas E., Herrera L.A., Sordo M., Gonsebatt M.E., Montero R., Rodriguez R., Ostrosky-Wegman P. Mitotic index and cell proliferation kinetics for identification of antineoplastic activity. Anti-Cancer Drugs. 4:1993;637-640.
22. M Antoshina M., Porjadkova N.A. A technique for differential staining of sister chromatide without using fluorochrome. Cytol. Genet. 4:1978;349-352.
23. Kelsey K.T., Christiani D.C., Wiencke J.K. Bimodal distribution of sensitivity to SCE induction by diepoxybutane in human lymphocytes. II. Relationship to baseline SCE frequency. Mutat. Res. 248:1991;27-33.
24. Laffon B., Pásaro E., Méndez J. Genotoxic effects of styrene-7,8-oxide in human white blood cells: comet assay in relation to the induction of sister-chromatid exchanges and micronuclei. Mutat. Res. 491:2001;163-172.
25. Vian L., Bichet N., Gouy D. The in vitro micronucleus test on isolated human lymphocytes. Mutat. Res. 291:1993;93-102.
26. Fenech M. The in vitro micronucleus technique. Mutat. Res. 455:2000;81-95.
27. Montero-Montoya R., Serrano L., Ostrosky-Wegman P. In vitro induction of micronuclei in lymphocytes: the use of bromodeoxyuridine as a proliferation marker. Mutat. Res. 391:1997;135-141.
28. Lecointe P., Macquet J-P., Butour J-L., Paoletti C. Relative efficiencies of a series square-planar platinum(II) compounds on Salmonella mutagenesis. Mutat. Res. 48:1977;139-144.
29. Beck D., Fisch J.E. Mutagenicity of platinum coordination complexes in Salmonella typhimurium. Mutat. Res. 77:1980;45-54.
30. Mattern I.E., Cochiarella L., van Kralingen C.G., Lohman P.H.M. Prophage induction and mutagenicity of a series of anti-tumor platinum(II) and platinum(IV) co-ordination complexes. Mutat. Res. 95:1982;79-93.
31. Hannan M.A., Al-Dakan A.A., Hussain S.S., Amer M.H. Mutagenicity of cisplatin and carboplatin used alone and in combination with four other anticancer drugs. Toxicology. 55:1989;183-191.
32. Collucia M., Correale M., Fanizzi F.P., Giordano D., Maresca L., Mariggio M.A., Natile G., Tamaro M. Mutagenic activity of some platinum complexes: chemical properties and biological activity. Toxicol. Environ. Chem. 8:1984;1-8.
33. Jordan P., Carmo-Fonesca M. Molecular mechanisms involved in cisplatin cytotoxicity. Cell Mol. Life Sci. 57:2000;1229-1235.
34. Kelland L.R. Preclinical perspectives on platinum resistance. Drugs. 59:2000;1-8.
35. Gatehouse D., Haworth S., Cebula T., Gocke E., Kier L., Matsushima T., Melcion C., Nohmi T., Ohta T., Venitt S., Zeiger E. Recommendations for the performance of bacterial mutation assays. Mutat. Res. 312:1994;217-233.
36. Uno Y., Morita M. Mutagenic activity of some platinum and palladium complexes. Mutat. Res. 298:1993;269-275.
37. Benedict W.F., Baker M.S., Haroun L., Choi E., Ames B.N. Mutagenicity of cancer chemotherapeutic agents in the Salmonella/microsome test. Cancer Res. 37:1977;2209-2213.
38. Ren M.Q., Kuhn G., Wegner J., Nürnberg G., Chen J. Feeding daidzen to late pregnant sows influences the estrogen receptor beta and type 1 insulin-like growth factor receptor mRNA expression in newborn piglets. J. Endocrinol. 170:2001;129-135.
39. Kulling S.E., Rosenberg B., Jacobs E., Metzler M. The phytoestrogens coumoestrol and genistein induce structural chromosomal aberrations in cultured human peripheral blood lymphocytes. Arch. Toxicol. 73:1999;50-54.
40. Ciesielska E., Studzian K., Zyner E., Ochocki J., Szmigiero L. DNA damage and apoptosis induction in L1210 cells by cis-diamminedichloroplatinum (II) and its new aminoflavone analogue. Cell. Mol. Biol. Lett. 5:2000;441-450.
41. Sakagami H., Jiang Y., Kusama K., Atsumi T., Ueha T., Toguchi M., Iwakura I., Satoh K., Fukai T., Nomura T. Induction of apoptosis by flavones, flavonols (3-hydroflavones) and isoprenoid-substituted flavonoids in human oral tumor cell lines. Anticancer Res. 20:2000;271-278.
42. Sanderson B.J.S., Shield A.J. Mutagenic damage to mammalian cells by therapeutic alkylating agents. Mutat. Res. 355:1996;41-57.
43. Racz I., Tory K., Gallyas F., Berente Z., Osz E., Jaszlits L., Bernath S., Sumegi B., Rabloczky G., Literati-Nagy P. BGP-15 - a novel poly(ADP-ribose) polymerase inhibitor - protects against nephrotoxicity of cisplatin without compromising its antitumor activity. Biochem. Pharmacol. 63:2002;1099-1111.
44. Lee R.H., Song J.M., Park M.Y., Kang S.K., Kim Y.K., Jung J.S. Cisplatin-induced apoptosis by translocation of endogenous Bax in mouse collecting duct cells. Biochem. Pharmacol. 62:2001;1013-1023.
45. Antunes L.M.G., Araújo M.C.P., Darin J.C., Binachi M.P. Effects of the antioxidants curcumin and vitamin C on cisplatin-induced clastogenesis in Wistar rat bone marrow cells. Mutat. Res. 465:2000;131-137.
46. Srb V., Kubzová E., Kubíková K. chromosome aberration and mitotic activity in human peripheral blood lymphocytes following in vitro action of platinum cytostatics cis-DDP and EM-Pt. Neoplasma. 33:1986;465-469.
47. Wiencke J.K., Cervenka J., Paulus H. Mutagenic activity of anticancer agent cis-dichlorodiammine platinum-II. Mutat. Res. 68:1979;69-77.
48. Meyene J., Lockhart L. Cytogenetics effects of cis-platinum(II) diamminedichloride on human lymphocyte cultures. Mutat. Res. 58:1978;87-97.
49. Meyne J., Lockhart L.H., Arrighi F.E. Nonrandom distribution of chromosomal aberrations induced by three chemicals. Mutat. Res. 63:1979;201-209.
50. 2 phase and cell death induced by cisplatin. J. Natl. Cancer Inst. 82:1990;749-755.
51. Herrera L.A., Tittelbach H., Gebhart E., Ostrosky-Wegman P. Changes in the prolifertion of human lymphocytes induced by several cytostatics and revealed by the premature chromosome condensation technique. Mutat. Res. 263:1991;101-106.
52. Blaško M., Kvietiková I., Plešková I., Chalupa I., Kuliffay P., Sirack? J. Cytogenetic changes of human peripheral blood lymphocytes in vivo after exposure to cis-DDP (cis- diamminedichloroplatinum II) and oxo-Pt (cis-diamminedichloro-trans- dihydroplatinum IV). Neoplasma. 34:1987;235-238.
53. Shinkai T., Saijo N., Eguchi K., Sasaki Y., Tamura T., Sakurai M., Suga J., Nakano H., Nakagawa K., Hong W.-S., Nakajima T. Cytogenetic effect of carboplatin on human lymphocytes. Cancer Chemother. Pharmacol. 21:1988;203-207.
54. Ponzanelli I., Landi S., Bernacchi F., Barale R. The nature of high frequency sister chromatid exchange cells (HFCs). Mutagenesis. 12:1997;329-333.
55. Stopper H., Müller S.O. Micronuclei as a biological endpoint for genotoxicity: a minireview. Toxicol. In Vitro. 11:1997;661-667.
56. Cipp D.H., Singh R.P. The mutagenic effects of cis-platinum(II) diammine dichloride (CPDD) and CPDD plus caffeine. Mutat. Res. 122:1983;111-113.
57. Phelps J.B., Garriott M.L., Hoffman W.P. A protocol for the in vitro micronucleus test. II. Contributions to the validation of a protocol suitable for regulatory submissions from an examination of 10 chemicals with different mechanisms of action and different levels of activity. Mutat. Res. 521:2002;103-112.
58. Pietras T., Kakowski R., Zyner E., Stolarek R., Ochocki J., Musil A., Nowak D., Glinka R. Deoxyribose degradation by cis-platinum and its derivatives choline. J. Cosmet. 4:1998;177-180.
59. B. Kosmider, R. Osiecka, E. Ciesielska, L. Szmigiero, E. Zyner, J. Ochocki, Induction of apoptosis and necrosis in lymphocytes by the cis-Pt(II) complex of 3-aminoflavone in comparison with cis-DDP, Mutat. Res. (2004) in press.